Details for New Drug Application (NDA): 217714
✉ Email this page to a colleague
NDA 217714 describes ESOMEPRAZOLE MAGNESIUM, which is a drug marketed by Alkem Labs Ltd, Amneal Pharms Ny, Aurobindo Pharma Ltd, Cipla, Cisen, Cspc Ouyi, Dr Reddys, Ethypharm, Glenmark Speclt, Granules, Graviti Pharms, Guangzhou Novaken, Hec Pharm, Hetero Labs Ltd Iii, Indchemie Health, Lannett Co Inc, Macleods Pharms Ltd, Mylan, Prinston Inc, Sun Pharm, Torrent, Zhejiang Yongtai, Zydus Pharms, Aurobindo Pharma, Guardian Drug, Marksans Pharma, Perrigo R And D, Pharmobedient, P And L, and Dexcel, and is included in fifty NDAs. It is available from one hundred and eleven suppliers. There are two patents protecting this drug. Additional details are available on the ESOMEPRAZOLE MAGNESIUM profile page.
The generic ingredient in ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium. There are seventy-four drug master file entries for this compound. One hundred and thirteen suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.
The generic ingredient in ESOMEPRAZOLE MAGNESIUM is esomeprazole magnesium. There are seventy-four drug master file entries for this compound. One hundred and thirteen suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium profile page.
Summary for 217714
| Tradename: | ESOMEPRAZOLE MAGNESIUM |
| Applicant: | Cipla |
| Ingredient: | esomeprazole magnesium |
| Patents: | 0 |
Pharmacology for NDA: 217714
| Mechanism of Action | Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors |
Suppliers and Packaging for NDA: 217714
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 217714 | ANDA | Cipla USA Inc. | 69097-507 | 69097-507-31 | 30 FOR SUSPENSION in 1 CARTON (69097-507-31) |
| ESOMEPRAZOLE MAGNESIUM | esomeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 217714 | ANDA | Cipla USA Inc. | 69097-508 | 69097-508-31 | 30 FOR SUSPENSION in 1 CARTON (69097-508-31) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION, DELAYED RELEASE;ORAL | Strength | EQ 2.5MG BASE/PACKET | ||||
| Approval Date: | Jan 7, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION, DELAYED RELEASE;ORAL | Strength | EQ 5MG BASE/PACKET | ||||
| Approval Date: | Jan 7, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
